Literature DB >> 28001222

Secondary bacterial isolates from previously untreated Buruli ulcer lesions and their antibiotic susceptibility patterns in Southern Nigeria.

Moses Chibueze Anyim1, Anthony Obiamaka Meka1, Joseph Ngozi Chukwu1, Charles Chukwunalu Nwafor1, Daniel Chukwunweolu Oshi1,2, Nelson Okechukwu Madichie1, Ngozi Ekeke1, Chukwuka Alphonsus1, Obinna Mbah1, Chinenye Nwaekpe3, Martin Njoku4, Dare Fakiyesi4, Vitalis Ulodiaku5, Ignatius Ejiofor6, Adeniyi Hakeem Bisiriyu7, Kingsley Nnanna Ukwaja8.   

Abstract

INTRODUCTION: : Mycolactones, secreted by Mycobacterium ulcerans, were previously believed to prevent super infection in Buruli ulcer lesions. However, little is known about secondary bacterial infections in these lesions. This study evaluated contaminating bacterial flora and their antibiotic susceptibility patterns in cases of previously untreated Buruli ulcer disease from three states in Southern Nigeria.
METHODS: A prospective analysis was conducted between January and June of 2015 using wound swabs from eligible patients with Buruli ulcer disease, confirmed by quantitative-polymerase chain reaction, with active ulcers. Microbiological analyses including isolation of bacteria, species identification of isolates, and drug susceptibility tests were performed.
RESULTS: Of 51 patients, 27 (52.9%) were female. One or more bacterial species of clinical importance was isolated from each patient. A total of 17 different microbial species were isolated; 76.4% were Gram-negative and 23.6% were Gram-positive isolates. The most common bacterial species detected was Staphylococcus aureus (24%), followed by Aeromonas hydrophila (13%), Pseudomonas aeruginosa (13%), and Klebsiella pneumoniae (11%). Drug susceptibility tests showed a particularly high frequency of resistance to commonly used antimicrobials in Nigeria for Staphylococcus aureus.
CONCLUSIONS: Super bacterial infections occur in Buruli ulcer lesions in Nigeria, and these infections are associated with high rates of resistance to commonly used antibiotics in the country.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28001222     DOI: 10.1590/0037-8682-0404-2016

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  5 in total

1.  Responses to chemical cross-talk between the Mycobacterium ulcerans toxin, mycolactone, and Staphylococcus aureus.

Authors:  Laxmi Dhungel; Lindsey Burcham; Joo Youn Park; Harshini Devi Sampathkumar; Albert Cudjoe; Keun Seok Seo; Heather Jordan
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

2.  Report of a series of 82 cases of Buruli ulcer from Nigeria treated in Benin, from 2006 to 2016.

Authors:  Gilbert Adjimon Ayelo; Esai Anagonou; Anita Carolle Wadagni; Yves Thierry Barogui; Ange Dodji Dossou; Jean Gabin Houezo; Julia Aguiar; Roch Christian Johnson; Raoul Saizonou; Kingsley Asiedu; Ghislain Emmanuel Sopoh
Journal:  PLoS Negl Trop Dis       Date:  2018-03-09

3.  Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.

Authors:  Elizabeth Gyamfi; Charles A Narh; Charles Quaye; Adiza Abbass; Bartholomew Dzudzor; Lydia Mosi
Journal:  BMC Microbiol       Date:  2021-01-05       Impact factor: 3.605

4.  Assessment of community knowledge, attitude, and stigma of Buruli ulcer disease in Southern Nigeria.

Authors:  Charles Chukwunalu Nwafor; Anthony Meka; Joseph Ngozi Chukwu; Ngozi Ekeke; Chukwuka Alphonsus; Obinna Mbah; Nelson Okechukwu Madichie; Ufuoma Aduh; Matthew Ogbeifo; Bola Olubakin IseOluwa-Adelokiki; Joseph Ezebunafor Edochie; Joseph Ushaka; Kingsley Nnanna Ukwaja
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

5.  Rapid detection of Mycobacterium ulcerans with isothermal recombinase polymerase amplification assay.

Authors:  Michael Frimpong; Hubert Senanu Ahor; Ahmed Abd El Wahed; Bernadette Agbavor; Francisca Naana Sarpong; Kenneth Laing; Mark Wansbrough-Jones; Richard Odame Phillips
Journal:  PLoS Negl Trop Dis       Date:  2019-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.